News Column

BLUEBIRD BIO, INC. FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits

July 30, 2014

Item 8.01 Other Events.

In connection with its acquisition of all of the outstanding capital stock of Precision Genome Engineering, Inc. ("Pregenen") and the issuance of shares of common stock (the "Shares") of bluebird bio, Inc. (the "Company") to the former stakeholders of Pregenen, the Company filed a prospectus supplement to its registration statement on Form S-3ASR (File No. 333-197192) on July 30, 2014 covering the resale of the Shares.

In connection with the resale of the Shares, the Company is filing the opinion of Goodwin Procter LLP as Exhibit 5.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits 5.1 Opinion of Goodwin Procter LLP. 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1 above).


For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Edgar Glimpses

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters